Desloratadine Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 370

Clinical Trials

Numerous clinical trials evaluate the therapeutic profile of desloratadine across diverse indications, focusing primarily on allergic conditions—such as seasonal and perennial allergic rhinitis, chronic urticaria, rhinorrhea, and post-nasal drip—alongside exploratory studies in heat illness, rheumatoid arthritis, and ulcerative colitis. Spanning Phase 1 through Phase 4 trials as well as post-marketing surveillance, these studies are sponsored by academic institutions and pharmaceutical entities, with recruitment statuses ranging from planned and active to completed or suspended.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07109817	RECRUITING	Breast Cancer; Peripheral Neuropathy	Montefiore Medical Center	2026-09	PHASE2
NCT07566351	RECRUITING	Rheumatoid Arthritis	Horus University	2026-04-23	PHASE2
NCT07333716	RECRUITING	Ulcerative Colitis (UC); Ulcerative Colitis	Tanta University	2026-01-26	PHASE2
NCT07632872	RECRUITING	Rheumatoid Arthritis (RA); Rheumatoid Arthritis	Horus University	2026-05-23	PHASE2
NCT07486583	NOT_YET_RECRUITING	Chronic Idiopathic Urticaria	Cairo University	2026-04-30	PHASE3
NCT06916884	COMPLETED	Allergic Rhinitis	Laboratorios Silanes S.A. de C.V.	2024-11-11	PHASE3
NCT05214911	COMPLETED	Allergic Rhinitis	Eurofarma Laboratorios S.A.	2024-07-08	PHASE3
NCT06272409	NOT_YET_RECRUITING	Allergic Rhinitis	EMS	2025-02-15	PHASE3
NCT06272409	Not yet recruiting	Allergic Rhinitis	EMS	2025-02-15	Phase 3
NCT06217367	UNKNOWN	Heat Illness; Allergic Rhinitis; Heat Injury; Sudomotor Sympathetic Dysfunction	Lakehead University	2023-12-05	PHASE4
NCT06268470	UNKNOWN	Chronic Urticaria	Chulalongkorn University	2018-06-01	PHASE2
NCT05446480	UNKNOWN	Heat Stress, Exertional; Inflammatory Response; Firefighter Personal Protective Equipment	University of Victoria	2022-07
NCT05232825	COMPLETED	Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis	Hoffmann-La Roche	2022-05-03	PHASE3
NCT02904304	SUSPENDED	Cold	Ache Laboratorios Farmaceuticos S.A.	2020-12	PHASE3
NCT02904304	Suspended	Cold	Ache Laboratorios Farmaceuticos S.A.	2020-12	Phase 3
NCT02646020	COMPLETED	Non-small Cell Lung Cancer	Sun Yat-sen University	2015-12	PHASE2
NCT04399525	COMPLETED	Pruritus	Universitaire Ziekenhuizen KU Leuven	2019-10-28
NCT04399148	COMPLETED	Pruritus	Universitaire Ziekenhuizen KU Leuven	2019-06-11
NCT01529242	TERMINATED	Cutaneous Hypersensitivity	EMS	2014-02	PHASE3
NCT02320396	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2015-01-09	PHASE3
NCT01529229	COMPLETED	Allergic Rhinitis	EMS	2013-11	PHASE3
NCT00967967	SUSPENDED	Asthma; Rhinitis	Laval University	2009-03
NCT01985789	COMPLETED	Asthma	Don Cockcroft	2013-11	PHASE4
NCT01916980	COMPLETED	Eczema; Dermatitis; Dermal Pruritus	Organon and Co	2013-08-27	PHASE3
NCT01916967	COMPLETED	Urticaria	Organon and Co	2013-08-27	PHASE3
NCT01918033	COMPLETED	Perennial Allergic Rhinitis	Organon and Co	2013-08-20	PHASE3
NCT01940393	COMPLETED	Urticaria	Grupo de Alergología Clínica y Experimental	2013-08	PHASE4
NCT01720485	UNKNOWN	Allergic Rhinitis	EMS	2013-10	PHASE3
NCT01400828	COMPLETED	Seasonal Allergic Rhinitis	Yuhan Corporation	2011-06	PHASE3
NCT02507635	COMPLETED	Allergic Rhinitis	Iuliu Hatieganu University of Medicine and Pharmacy	2009-02	PHASE4
NCT01444196	COMPLETED	Urticaria	Marcus Maurer	2009-08	PHASE4
NCT00598611	COMPLETED	Chronic Urticaria	Charite University, Berlin, Germany	2007-09	PHASE3
NCT00536380	COMPLETED	Chronic Idiopathic Urticaria	Organon and Co	2007-09	PHASE4
NCT00633919	COMPLETED	Allergy	ALK-Abelló A/S	2006-07	PHASE2; PHASE3
NCT00405964	COMPLETED	Allergic Rhinitis	Organon and Co	2006-09	PHASE3
NCT00862225	COMPLETED	Seasonal Allergic Rhinitis	Max Zeller Soehne AG	2008-01	PHASE2
NCT00761527	Completed	Rhinitis Allergic Seasonal\|Rhinitis Allergic Perennial\|Urticaria	Organon and Co	2008-03	--
NCT00406783	COMPLETED	Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial	Organon and Co	2006-08	PHASE3
NCT00600847	COMPLETED	Acquired Cold Urticaria	Charite University, Berlin, Germany	2006-11	PHASE4
NCT00424580	COMPLETED	Asthma	University of Saskatchewan	2007-01
NCT00264303	COMPLETED	Chronic Idiopathic Urticaria	UCB Pharma	2005-12	PHASE4
NCT00359138	COMPLETED	Hypersensitivity	Organon and Co	2006-02	PHASE4
NCT01314352	COMPLETED	Fed	Dr. Reddy's Laboratories Limited	2005-12	PHASE1
NCT01314339	COMPLETED	Fasting	Dr. Reddy's Laboratories Limited	2005-12	PHASE1
NCT00779116	COMPLETED	Allergies	Organon and Co	2005-09	PHASE4
NCT00780403	COMPLETED	Allergies	Organon and Co	2005-08	PHASE4
NCT00160589	COMPLETED	Rhinitis, Allergic, Perennial	UCB Pharma	2005-04	PHASE4
NCT00160537	COMPLETED	Seasonal Allergic Rhinitis	UCB Pharma	2005-05	PHASE4
NCT00816972	COMPLETED	Post-nasal Drip; Seasonal Allergic Rhinitis; Rhinorrhea	Organon and Co	2005-04	PHASE2
NCT00311844	COMPLETED	Conjunctivitis, Allergic	Organon and Co	2005-03-01	PHASE4
NCT00751218	COMPLETED	Urticaria	Organon and Co	2004-05-06	PHASE4
NCT00751166	TERMINATED	Urticaria	Organon and Co	2004-03-01	PHASE4
NCT00795522	COMPLETED	Urticaria	Organon and Co	2003-07	PHASE4
NCT00521170	COMPLETED	Allergy	UCB Pharma	2004-11	PHASE1
NCT00779636	COMPLETED	Allergic Airway Disease	Organon and Co	2003-07-01	PHASE4
NCT00794378	COMPLETED	Allergic Rhinitis	Organon and Co	2004-11	PHASE3
NCT00794794	COMPLETED	Allergic Rhinitis	Organon and Co	2004-11	PHASE3
NCT00783146	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2004-08-01	PHASE4
NCT00783211	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2004-08-01	PHASE4
NCT00789152	COMPLETED	Allergic Rhinitis	Organon and Co	2003-12-01	PHASE3
NCT00783354	COMPLETED	Urticaria; Chronic Idiopathic Urticaria	Organon and Co	2003-04-01	PHASE4
NCT00795158	COMPLETED	Urticaria	Organon and Co	2002-11	PHASE3
NCT00757562	COMPLETED	Chronic Idiopathic Urticaria; Atopy	Organon and Co	2002-11-01	PHASE3
NCT01108783	COMPLETED	Seasonal Allergic Rhinitis	Faes Farma, S.A.	2003-04	PHASE3
NCT00794599	COMPLETED	Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis	Organon and Co	2002-12	PHASE4
NCT00805324	COMPLETED	Rhinitis, Allergic, Seasonal; Asthma	Organon and Co	2003-05	PHASE3
NCT00794768	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2002-11	PHASE4
NCT00817076	COMPLETED	Dermatitis, Atopic	Organon and Co	2003-03	PHASE3
NCT00794495	COMPLETED	Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis	Organon and Co	2002-12	PHASE4
NCT00783133	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2002-11-01	PHASE4
NCT00805584	COMPLETED	Rhinitis, Allergic, Seasonal	Organon and Co	2003-05	PHASE4
NCT00794846	COMPLETED	Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis	Organon and Co	2002-12	PHASE4
NCT00794248	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2002-11	PHASE4
NCT00867191	COMPLETED	Seasonal Allergic Rhinitis	Organon and Co	2002-02-01	PHASE4
NCT01506050	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-01	PHASE1
NCT01506037	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-01	PHASE1
NCT01373138	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-04	PHASE1
NCT01506791	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-04	PHASE1
NCT00636870	COMPLETED	Allergic Rhinitis	Sanofi	2003-02	PHASE4
NCT00637585	COMPLETED	Allergic Rhinitis	Sanofi	2002-12	PHASE4
NCT00346606	UNKNOWN	Chronic Idiopathic Urticaria; Urticaria	Lotus Pharmaceutical	2006-01	PHASE4

(data from https://clinicaltrials.gov, updated on 2026-08-26)

Check the Desloratadine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Desloratadine functions as a potent antagonist of the human histamine H1 receptor (IC50 = 51 nM), selectively binding to the receptor to prevent histamine-induced activation of downstream signaling pathways and subsequent proinflammatory mediator release from mast cells and basophils. By suppressing endothelial permeability, mucosal edema, and smooth muscle constriction, this targeted inhibition alleviates allergic symptoms such as rhinorrhea, nasal congestion, and pruritus in clinical conditions including allergic rhinitis and urticaria.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).